Cancer immunotherapy: the beginning of the end of cancer?
By S. Farkona, Eleftherios P. Diamandis, I. Blasutig. BMC Medicine, 2016
1,070 citations recorded by the source corpus.
These are exciting times for cancer immunotherapy. After many years of disappointing results, the tide has finally changed and immunotherapy has become a clinically validated treatment for many cancers. Immunotherapeutic strategies include cancer vaccines, oncolytic viruses, adoptive transfer of ex vivo activated T and natural killer cells, and administration of antibodies or recombinant proteins that either costimulate cells or block the so-called immune checkpoint pathways. The recent success of several immunotherapeutic regimes, such as monoclonal antibody blocking of cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD1), has boosted the development of this treatment modality, with the consequence that new therapeutic targets and schemes which combine various immunological agents are now being described at a breathtaking pace. In this review, we outline some of the main strategies in cancer immunotherapy (cancer vaccines, adoptive cellular immunotherapy, immune checkpoint blockade, and oncolytic viruses) and discuss the progress in the synergistic design of immune-targeting combination therapies.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/7a62b5c448f2b0e5ca65f084ae9e40a77af289c2
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Oncology
Citations in the corpus
- Personalized medicine: motivation, challenges, and progress. (2018, background): “(24) A second example involves the emerging set of cancer treatments known as immunotherapies.(25) Although there are many types of immunotherapies, all of them seek to prime or trigger an individual's own immune system to attack a cancer.”
- The PI3K pathway in human disease (2017, positive): “responses seen in patients with normally intractable metastatic cancers (Farkona et al., 2016; Pardoll, 2012).”
- TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis (2019, background): “Despite demonstrable progress, these strategies frequently deliver relatively modest improvements in disease outcomes owing to acquired resistance and excessive toxicity [3].”
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) (2019, neutral): “tem activity to eradicate cancerous cells [31].”